How can Klarity help with my GLP-1 treatment
Priority Review designation is possible given the magnitude of the trial results, which could shorten this timeline to 6 months
Gastrointestinal adverse events Compared with placebo, nausea was more frequent with all tirzepatide doses, especially 15 mg (OR 5.60 [95% CI 3.12, 10.06], I 2 0%) (Table 2)
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
As individuals age, NAD+ levels naturally decline, which has led to interest in supplementation with NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)
Over time, this chain reaction can translate to fatigue, slower metabolism, decreased strength, and loss of lean muscle masseven as the scale continues to drop